GlassScriptPhysician profile
Mounzer E Agha
NPI 1669442638
$12,759.54
in general payments reported to CMS, 2019-2025
12 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,611 · 2020: $4,598 · 2021: $46.18 · 2023: $200 · 2024: $135 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verastem, INC. | $6,061.87 | 2019 | |
| Secura Bio, INC. | $4,598.46 | 2020 | |
| Janssen Research & Development, LLC | $1,405.47 | 2019 | |
| Celgene Corporation | $143.47 | 2019 | |
| Genmab U.S., INC. | $134.68 | 2024 | |
| Adc Therapeutics America, INC. | $132.72 | 2025 | |
| Seagen INC. | $101.12 | 2023 | Adcetris |
| Janssen Scientific Affairs, LLC | $98.44 | 2023 | Imbruvica, Balversa, Darzalex |
| Acrotech Biopharma INC. | $23.94 | 2021 | |
| Servier Pharmaceuticals LLC | $22.24 | 2021 | |
| Beone Medicines USA, INC. | $22.15 | 2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $14.98 | 2025 | Calquence |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mounzer Agha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.